This study examined the relationship between transcapillary insulin-transport and insulin action in vivo. During euglycemic clamps (n = 7) in normal conscious dogs we simultaneously measured plasma and thoracic duct lymph insulin and glucose utilization (Rd). Clamps consisted of an activation phase with constant insulin infusion (0.6 mU/kg per min) and a deactivation phase. 14CIInulin was infused as a passively transported control substance. While [14Cjinulin reached an equilibrium between plasma and lymph, steady-state (ss) plasma insulin was higher than lymph (P < 0.05) and the ratio of 3:2 was maintained during basal, activation, and deactivation phases: 18±2 vs. 12±1, 51±2 vs. 32±1, and 18±3 vs. 13±1 ,U/ml. In addition, it took longer for lymph insulin to reach ss than plasma insulin during activation and deactivation: 11±2 vs.
1. Abbreviations used in this paper: Ginf, glucose infusion rate; HGO, hepatic glucose output; NIDDM, non-insulin-dependent diabetes mellitus; Rd, glucose utilization. from plasma to the cell surface (7) (8) (9) (10) , (b) receptor binding (1 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] , (c) activation of tyrosine kinase (14, 15) , (d) translocation of glucose transporters from the cell interior to the cell membrane (16) (17) (18) (and/or transporter activation), (e) glucose phosphorylation, and (f) postphosphorylation metabolic events. While major efforts in the last decade have concentrated on postinsulin transport events, the process and significance of the movement of insulin from the plasma to the surface of the cell in determination of the time course and efficiency of insulin action has received surprisingly little attention.
When insulin is infused intravenously, attainment of steady-state Rd lags steady-state plasma insulin levels by several hours (19, 20) . The delay in expression of insulin action may be attributed to the transport of insulin from the blood to insulin-sensitive cells, receptor binding and/or to postreceptor binding events. However, when insulin is added to cell cultures in vitro, no delays of similar length are observed (11, 21). Therefore, insulin transport to the interstitial medium bathing the insulin-sensitive cells emerges as a likely cause ofthe delay.
There is evidence supporting the concept that the movement of insulin into the interstitium, which precedes the binding of insulin to its receptor, is an important rate-determining step in insulin action. King and his colleagues (8, 9, 22, 23) have demonstrated that the movement of insulin across the capillary endothelial cell in vitro is rapid, and they have provided evidence that such transport is a receptor-mediated process. Rasio et al. (10, 24, 25) reported a measurable delay between changes in plasma versus lymph insulin during intravenous glucose tolerance tests. Also, while they did not measure interstitial insulin directly, Sherwin and his colleagues (20, 26) used kinetic analysis to demonstrate a correlation between the calculated level of insulin in a compartment remote from plasma, and the rate of Rd.
Thus, previous investigators have suggested that the movement of insulin from blood into the interstitium is an important determinant of the rate, if not the absolute magnitude of insulin action in vivo. Clearly, this insulin transport process could have important significance if it was altered in insulinresistant states, such as NIDDM. However, direct measurements of the so-called "remote" compartment from which insulin expresses its action have been very limited. Also, there have not previously been temporal comparisons of lymph insulin concentration and the rate of Rd. To gather additional information we designed the present study to directly measure the time required for insulin transport to the interstitium as a necessary step in the exegesis of the time course and mechanism of insulin action. This was accomplished by measuring plasma and lymph insulin (which is derived from interstitial fluid) while simultaneously assessing whole body Rd during euglycemic hyperinsulinemic clamps. Methods Surgical procedure. Surgery was performed on five individual animals at least 5 d before the first experiment. The short interval between surgery and the first study was required to guarantee patency of chronic thoracic duct catheters. In two animals we were able to do two experiments; studies were separated by 4 d.
The surgical procedure was as follows: after an overnight fast, dogs were anesthetized with Halothane and nitrous oxide. To aid in the identification of the thoracic duct, dogs were given 2-3 liters of saline during the first 90 min of the surgery to increase lymph flow. One catheter was inserted in the right internal jugular vein and advanced into the right atrium as described previously (27) . After the longitudinal incision on the left side ofthe neck parallel to the internal jugular vein, the thoracic duct was identified beneath the junction of the internal jugular and subclavian veins. A Tygon catheter was introduced into the duct and secured. The external end of the thoracic duct catheter was connected to the end of a second cannula, itself secured in the left external jugular vein (28) . This procedure established an external lymph/venous blood anastomosis, which effectively maintained continuous drainage of lymphatic flow to minimize clotting within the thoracic duct catheter between and during experiments when lymph collection was not required. After exteriorization, all catheters were placed in a small bag situated at the back of the neck and protected with a heavy denim collar.
Patency of the thoracic duct catheter was checked daily, and dogs were given 3,000 to 4,000 IU ofheparin (Elkins-Sinn, Inc., Cherry Hill, NJ) subcutaneously each morning (except on experiment days) and evening to prevent clot formation. Catheter location was confirmed at necropsy in all animals.
Experimental protocol. A total of seven euglycemic glucose clamp experiments are reported herein, in which plasma and lymph samples were collected. During the experiments dogs were in a conscious, relaxed state. Animals rested in a Pavlov sling and were given free access to water. Each 6-h clamp consisted ofan activation phase during which a 3-h constant insulin infusion was administered, and a 3-h deactivation phase after termination of the infusion.
At 0730, after an overnight fast, three intravenous intracatheters (Deseret Medical, Sandy, UT) were inserted: in the left cephalic vein for infusion of tracer to assess glucose turnover, and in the left and right saphenous veins for infusions of porcine insulin and 20% dextrose (Kendall McGaw, Irvine, CA), respectively.
As previously recommended (29) a tracer quantity of [3-3H] The rate constants (k) of the decay data for plasma and lymph insulin, Rd and HGO in the deactivation phase were determined by fitting data to mono-exponential curves using the MLAB modeling package (37) on a DEC-10 computer (Digital Electronics, Maynard, MA).
Statistical tests were performed with the Statfast program (38) on an IBM personal computer. All statistical comparisons were done using Student's paired and unpaired t tests. Data are reported as mean±SE.
Results
Basal. Basal endogenous glucose production was 2.6±0.1 mg/kg per min. Interestingly, fasting basal glucose and insulin concentrations in lymph were not equal to glucose and insulin in plasma (Table I) : glucose was slightly higher in lymph (102±2 vs. 96±2 mgfdl; P < 0.05) while insulin was considerably lower in lymph than in plasma (12±1 vs. 18±2 MU/ml; P < 0.02). There was no difference between plasma and lymph specific activity during the basal period (P > 0.4).
Clamp stability. Plasma glucose was successfully clamped at basal levels (96±2 mg/dl) with an average glucose infusion rate (Gino of 6.8±0.4 mg/kg per min at steady state (Figs. 1 A and C). The mean coefficient of variation for plasma glucose was 5±2%. Furthermore, use of "spiked" glucose infusate minimized the variation in plasma specific activity observed during clamps (Fig. 1 B) . Specific activity fell slightly to a minimum of 82% of the basal value after 2 h of insulin, and increased to a value just 19% above the basal by the end ofthe study. This relative consistency of specific activity during the clamp study is in contrast to a precipitous fall of plasma specific activity by unlabeled glucose infusion during clamp experiments, which results in incomplete mixing of labeled glucose in the glucose pool (39) .
The glucose concentrations in lymph (99±1 mg/dl) were similar to plasma (97±1 mg/dl) during the experiments (P > 0.5; Fig. 1 A) . At no time during the experiments was specific activity in lymph different from plasma (P > 0.05). Equivalence of plasma and lymph specific activity indicates that prelabeling the glucose infusate succeeded in achieving a homogenous extracellular glucose pool during glucose clamp experiments.
Inulin and insulin during the activation period. Inulin served as a reference molecule for transcapillary insulin transport since inulin, which has a similar molecular weight and size to insulin (30) , is apparently transported across the capillary endothelium by diffusion alone (40) . Following the initiation of the infusion (Fig. 2) , ["4C]inulin was first detected in lymph 6±1 min after its appearance in plasma, i.e., at 3±0.4 min in plasma vs. 9±1 min in lymph. Although appearance of lymph inulin was delayed compared to plasma inulin, its dy- During deactivation insulin behaved very differently from inulin. During the final 3 h, both plasma and lymph insulin Ldy-state were statistically different between returned to basal levels but again, lymph insulin was slower mph. The increase in lymph inulin to a level than insulin in plasma; plasma insulin returned to basal within lasma by 3 h is consistent with an absence of 8+2 minm while lymph insulin did not reach basal levels until thoracic duct lymph by any large molecule-free 32±6 min after termination of the insulin infusion ( Fig. 3 and lso consistent with the removal of inulin in the Table II) . The fractional disappearance rate of insulin from only from the plasma compartment, presum-lymph was much slower than that in plasma (k = 0.07±0.01 Ineys (41).
vs. 0.30±0.06 min-'; P < 0.02). Plasma insulin transiently iilarities in molecular size and weight, the dy-dropped below basal between 210 and 260 min (Fig. 3) , conulin distribution between plasma and lymph sistent with suppression of insulin secretion by exogenous inlifferent from those of inulin. The first contrast sulin (42) . However, the transient drop in plasma insulin was f the relative (plasma/lymph) steady-state levels not reflected in lymph insulin, and given that plasma insulin ig infusion (Fig. 3) ; while inulin in lymph at was generally higher than lymph hormone, there was no signifls equal to plasma inulin (Fig. 2) , insulin levels icant difference between insulin levels in plasma and lymph eady-state were much less than plasma insulin during this period (P > 0.3). The concentration difference bena insulin increased to 51±2 AU/ml but lymph tween plasma and lymph insulin was reestablished as plasma ed only to 32±1 AU/ml, 62±4% of the plasma insulin returned to basal levels during the last 100 min of the 2). Thus, the concentration gradient between deactivation phase. Thus, the ratio between steady-state plasma and lymph insulin levels also returned to 0.68±0. the milieu ofinsulin-responsive tissues, it is of interest to compare the time course of lymph insulin concentration with Rd. Such a comparison could reveal the extent to which insulin movement from plasma to lymph is rate-determinant in insulin action. As expected, insulin infusion into plasma increased Rd and suppressed HGO (Fig. 4) . During activation, Rd increased from basal (2.6±0.1) to steady-state of 6.6±0.4 mg/kg per min by 3 h (Table I) . Particularly striking is the tandem relationship between the relative increase in Rd and the increase in lymph insulin. The relative increases in these measurements were similar: the extent to which Rd increased (164±45%) was the same as the relative increase in lymph insulin (189±29%; P > 0.05; Fig. 5 ). More impressive is the comparative dynamics of lymph insulin and Rd:Rd reached steady-state within 50±8 min (Table II) , only 19 min after attainment of steady-state lymph insulin; this difference in mean time to attain steadystate did not reach statistical significance (P = 0.2). Following termination of the insulin infusion, Rd returned to basal levels within 45±14 min, which was not significantly different from the time for lymph insulin (32±6 min; P > 0.1). The rate constant for the decay in Rd (0.08±0.02 min-') was similar to lymph insulin (0.07±0.01 min-'; P > 0.7). The close relationship between lymph insulin and whole-body Rd even during dynamic changes in lymph insulin may be considered as a plot between these variables (Fig. 6) . While there was only a modest relationship between Rd and plasma insulin (r = 0.78; P < 0.01; Fig. 6 A) , the relationship between Rd and lymph insulin was very strong at basal, steady state, and even during the dynamic activation and deactivation phases (r = 0.95; P < 0.01; Fig. 6 B) . Thus, if lymph insulin can be hypothesized to be representative of interstitial insulin, Fig. 6 supports the concept that it is the transport to the interstitium that is ratelimiting in insulin action.
During insulin infusion, HGO was suppressed 89±4%, to 0.2±0.1 mg/kg per min. Prelabeling the glucose infusate ameliorated underestimation of endogenous glucose production due to incomplete mixing within glucose pool during the clamp experiments. The estimates of HGO were not significantly below zero at any time (Fig. 4) < 0.01; Fig. 7 ). After tial fluid (47, 48) . The thoracic duct is the largest lymph vessel 3O did not return to in the body and drains over two-thirds ofthe total body lymph. nriod (Fig. 4 and Table  Unlike Rasio, we did our experiments in conscious animals, teady-state of 1.7±0. 1 and we simultaneously measured glucose kinetics using the ictional disappearance isotope dilution principle. 8±0.03 min-'.
The present experiments represent the first report of the relationships between insulin in lymph and tracer-determined Rd. As expected, the moment-to-moment correlation between plasma insulin and Rd was weak (Fig. 6 A) , confirming the blood glucose concenconcept originally introduced by Sherwin and his colleagues )take by the peripheral that a remote insulin compartment must be the signal for Rd ly the most important (20, 26) . In contrast, there was a striking similarity between ipheral tissues to regulymph insulin and Rd during activation and deactivation rates to the liver, and phases of the euglycemic glucose clamps (Figs. 5 and 6 B) . Not luction (45) . Because only were these parameters correlated, but the proportional ,ceptor binding can be increase in Rd during the clamp was the same as that oflymph rstitial insulin conceninsulin. This proportionality between the two independently mntration in interstitial measured parameters is supportive of the concept that lymph in-sensitive cells which insulin does indeed represent the signal that determines Rd, pendent events. From and that lymph insulin represents interstitial insulin to which icterize the process by insulin-dependent cells are exposed. Of course, it is possible ulin receptors, i.e., the that this intimacy between lymph (i.e., interstitial) insulin and ary endothelium. The Rd is simply fortuitous. However, in more recent studies (data the in vivo kinetics of not shown) we have observed a similar proportionality beine the importance of tween lymph insulin and insulin action during the intravenous e interstitium on the glucose tolerance test (49) . Thus, it seems likely that measuring ; was accomplished by insulin in lymph does provide a "window" into the remote ymph insulin as well as compartment predicted by Sherwin and his colleagues, and erinsulinemic clamps.
supports the suggestion that Sherwin's remote insulin comia and/or somatostatin partment is interstitial insulin. I therefore lymph flow
In these studies, while we have assumed that thoracic duct y distribution kinetics lymph is representative of interstitial fluid in insulin-sensitive If the neuropeptide.
tissues, we are aware that under normal resting conditions the titial fluid insulin dymajor portion of the thoracic duct lymph is derived from the inherent in sampling abdominal viscera (50) . These tissues are in general not sensia sampling frequency tive to insulin, and insulin-increased Rd during euglycemic -tics. As an alternative, clamps occurs mainly at muscle tissues (44) . However, it is illeagues, who sampled reasonable that while we are not sampling muscle interstitial )f interstitial fluid (10, fluid, kinetics of insulin in the interstitium of abdominal viss that the composition cera and muscle tissue are quite similar. Evidence for this are similar to interstisimilarity is the intimate relationship between lymph insulin and Rd (Figs. 5 and 6 dude that it is the insulin transport process itself that is most responsible for the delay in insulin-stimulated Rd. The present studies demonstrate that it is the transport of insulin from plasma into interstitium which is rate limiting for insulin action in vivo.
The delay in insulin action cannot be totally accounted for by transendothelial transport. Our data suggest a small delay between lymph insulin and Rd (Fig. 5 and Table II) , although not consistently measurable. In the present studies, possible "modeling error" in Rd associated with the Steele equation (36) was minimized by the attainment of near-constant glucose specific activity during glucose clamps by using labeled exogenous glucose infusion (29) . However, while a finite delay between lymph insulin and Rd was not readily demonstrable, current knowledge of insulin action insists that this delay occurs, reflecting the time necessary for insulin binding and postreceptor binding cellular events. This is consistent with achievement of maximal glucose transport rates within 5 to 10 min of insulin administration in isolated hepatocytes (17) and muscle cells (21). Nonetheless, it seems clear that the transport of insulin from the plasma to the interstitium remains the primary factor responsible for the delay between changes in plasma insulin and Rd.
In the deactivation phase, no measurable delay between lymph insulin and Rd kinetics was observed (Fig. 5) . Not only was the time to reach steady-state for lymph insulin and Rd the same, but their fractional disappearance rates were also not different. Because plasma insulin declines rapidly at the cessation of the insulin infusion, the relationship between the rates of decline of interstitial insulin and Rd are independent of transport of insulin into the interstitial space. Therefore, while deactivation data cannot directly address the issue of transcapillary insulin transport, they are consistent with the concept that insulin transport to the interstitium is the rate-determining step.
It is also of interest to consider the relationship between insulin transport and the suppression of endogenous glucose production. The time course of mean suppression of HGO is plotted with that of mean lymph insulin in Fig. 7 . HGO was even more delayed than peripheral Rd with respect to lymph insulin. This is remarkable because liver sinusoids have larger gaps than the capillary endothelium in the peripheral insulinsensitive tissues such as muscle and adipose tissue. Thus we would expect insulin to reach hepatic cells quicker than the peripheral tissues. Furthermore, after the termination of the insulin infusion, HGO did not recover to basal levels within the 3-h observation period, while lymph insulin returned to basal within 32 min. One possible explanation for the result that HGO did not decline more quickly than Rd increased is that the primary effect of insulin to suppress HGO during clamps may be an indirect one to reduce gluconeogenic substrate flow (45) . If so, it would be expected that HGO would decline at the same rate as, or even slower than Rd would increase, as the effect of insulin on the peripheral tissues, i.e., to inhibit release of lactate, amino acids, or glycerol, could easily be slower than its effect to enhance glucose uptake. Alternatively, it is also possible that insulin may in fact act directly upon the liver to suppress HGO, but that induction and/or activation of key hepatic enzymes are responsible for the slower HGO dynamics.
To investigate the mechanism of insulin transport into the interstitium, we used ['4C]inulin, with a molecular weight similar to insulin, as a reference molecule to reflect passive transcapillary transport (40) . When inulin was infused intravenously, by 3 h an equilibrium was established between plasma and lymph inulin levels (Fig. 2) . Such an equilibrium would not have been expected if inulin were transported by an energy-dependent process, or if there were net utilization of inulin by cells. The steady-state relationships between plasma and lymph insulin were in sharp contrast to those of inulin. At basal, insulin concentrations in lymph were consistently lower than plasma, and a similarly positive 3:2 plasma/lymph insulin gradient was observed at hyperinsulinemic steady state (Fig.  3) . In addition to the steady-state difference, there were nonsteady state kinetic differences between insulin and ['4C]inulin distribution. Insulin appeared in lymph more slowly than inulin: after initiation of the infusion of both compounds, insulin increased in lymph 12 min after plasma, while lymph inulin increased but 6 min after plasma inulin. In addition, inulin reached steady state in lymph at approximately the same time as in plasma (Fig. 2) , while insulin in lymph took longer to reach steady state than in plasma (Fig. 3) . Thus, we observed a relative delay in insulin dynamics in lymph compared to inulin.
What may account for these differences between plasma and lymph insulin? Clearly, in steady-state, if lymph insulin is lower than plasma, one or more of the following possibilities must be true: (a) lymph is diluted with a volume ofmacromolecule-free filtrate, (b) a fixed proportion of insulin is degraded by endothelial cells as the peptide crosses the capillary, or (c) a significant mass of interstitial insulin is taken up by cells. Dilution of lymph is ruled out by the equality of plasma and lymph inulin at steady-state. Any macromolecule-free water dilution of lymph would dilute both molecules. Degradation of insulin by the capillary endothelial cells is not supported by the in vitro studies (23, 51) , in which most of insulin taken up by the cultured endothelial cells was recovered intact in the medium.
The most plausible explanation for the concentration gradient between plasma and lymph insulin is a substantial cellular uptake of insulin from the interstitial compartment. Such a concept is consistent with the known fate of receptor-bound insulin: migration into coated pits, internalization, and subsequent lysosomal degradation (52, 53) . These latter processes could account for the 3:2 concentration gradient at steady state observed for insulin, but lack of a gradient for inulin which presumably is not metabolized by cells. Furthermore, cellular uptake of insulin, not inulin, may affect the time course in lymph as well as the steady-state concentration. Intracellular insulin degradation will change free insulin concentration in lymph, which in turn may influence diffusion across the capillary wall. Lymph insulin levels may also be altered by retroendocytosis (54, 55) , a process by which internalized intact hormone is recycled to the plasma membrane and extruded into the interstitial space; however the quantitative importance of this reverse process in vivo is unclear. Lastly, one must be cautious of the use of inulin as a reference molecule for transcapillary insulin diffusion. While similar in molecular weight and diffusionary indices (32, 40, 56, 57) , their molecular composition is quite different (inulin is an inert polysaccharide, insulin a polypeptide), and thus their transport ultimately controlled by different biophysical factors.
It is important to reconcile our results with those of King and his colleagues (9) , who presented evidence that the movement of insulin through capillary endothelial cells in vitro is a unidirectional, receptor-mediated process. The presence of insulin receptors in vascular endothelial cells has been demonstrated (58, 59). If we assume that diffusion of insulin and inulin are similar, then the proposal of King et al. demands that insulin transport should be faster than transport by diffusion alone (i.e., inulin transport). However, our results indicate a delay oflymph insulin to reach steady state, relative to that of plasma insulin, findings at first glance apparently inconsistent with the hypothesis of King. However, one must be cognizent of the fact that lymph insulin dynamics are not determined solely by transcapillary transport processes. Rather they may be markedly affected by the extent to which insulin is taken up by cells. Thus the mechanisms by which insulin is transported across the capillary endothelial boundary in vivo remain to be elucidated.
In conclusion, the present data suggests that transcapillary insulin transport determines the delay in insulin action during clamps. If this transendothelial transport process were altered in pathologic states, it could have a substantial effect on insulin action. Prager and his colleagues (5) have demonstrated variability in the rates of insulin activation and deactivation in obesity. While it has been proposed by Lillioja et al. (60) that this "rate defect" could be related to dispersion of insulin through the interstitium, it seems equally likely that a capillary insulin transport defect could be responsible. Clearly, modulation of the number and/or affinity of putative capillary transporters would have substantial effects on the dynamics as well as efficacy ofinsulin action in vivo. The present results provide additional support for focusing on transcapillary insulin transport as a possible factor in the pathogenesis of glucose intolerance, diabetes, and other diseases in which insulin resistance is manifest.
